Zarxio

Monitor blood, including CBC and differential and platelets, before and during therapy (myelosuppressive chemotherapy: monitor twice weekly; BMT: monitor frequently; SCN: monitor during initial 4 weeks of therapy and during 2 weeks after dose adjustment) then monthly for the 1^st year. Discontinue if post nadir absolute neutrophil count (ANC) reaches 10,000/mm³ for patients receiving myelosuppressive chemotherapy; other indications: see full labeling. Monitor for splenomegaly/splenic rupture and for acute respiratory distress syndrome (ARDS); discontinue if ARDS occurs. Confirm diagnosis and do appropriate pretreatment hematological workup in SCN. Permanently discontinue if serious allergic reactions occur. Sickle cell disorders (discontinue if sickle cell crisis occurs). Evaluate if glomerulonephritis is suspected; consider dose reduction or interruption if causality is likely. Monitor for MDS/AML in those with severe chronic neutropenia, breast or lung cancer. Hold dose if cutaneous vasculitis occurs; resume at reduced dose after symptoms resolve and the ANC decreased. Avoid simultaneous chemo- and radiation therapy. Aortitis (discontinue if suspected). Latex allergy. Pregnancy. Nursing mothers.